Optimization of drug treatment of acromegaly (clinical and morphological comparison)
- Authors: Pronin E.V.1, Antsiferov M.B1, Alekseeva T.M1, Urusova L.S2, Lapshina A.M2, Mokrysheva N.G2
-
Affiliations:
- Endocrinological Dispensary of the Moscow Healthcare Department
- Reference Center for Pathomorphological, Immunohistochemical and Radiological Research Methods, National Medical Research Center for Endocrinology
- Issue: Vol 29, No 4 (2022)
- Pages: 44-52
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/320971
- DOI: https://doi.org/10.18565/pharmateca.2022.4.44-52
- ID: 320971
Cite item
Abstract
Full Text
About the authors
Evgeniy V. Pronin
Endocrinological Dispensary of the Moscow Healthcare Department
Email: r-wp@mail.ru
Endocrinologist
M. B Antsiferov
Endocrinological Dispensary of the Moscow Healthcare Department
T. M Alekseeva
Endocrinological Dispensary of the Moscow Healthcare Department
L. S Urusova
Reference Center for Pathomorphological, Immunohistochemical and Radiological Research Methods, National Medical Research Center for Endocrinology
A. M Lapshina
Reference Center for Pathomorphological, Immunohistochemical and Radiological Research Methods, National Medical Research Center for Endocrinology
N. G Mokrysheva
Reference Center for Pathomorphological, Immunohistochemical and Radiological Research Methods, National Medical Research Center for Endocrinology
References
- Akirov A., Asa S.L., Amer L., et al. The Clinicopathological Spectrum of Acromegaly. J. Clin Med. 2019;8(11):1962. Doi: 10.3390/ jcm8111962.
- Lopes M.B.S. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521-35. doi: 10.1007/s00401-017-1769-8.
- Syro L.V., Rotondo F., Serna C.A., et al. Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary Pituitary 2017;20(1):84-92. doi: 10.1007/s11102-016-0748-8.
- Cuevas-Ramos D., Carmichael J.D., Cooper O., et al. A structural and functional acromegaly classification. J. Clin Endocrinol Metab. 2015;100(1):122-31. doi: 10.1210/jc.2014-2468.
- Asa S.L., Kucharczyk W., Ezzat S. Pituitary acromegaly: not one disease. Endocr Relat Cancer. 2017;24(3):1- 4. doi: 10.1530/ERC-16-049.
- Bollerslev J., Heck A., Olarescu N.C. Management of endocrine disease: individualised management of acromegaly. Eur J. Endocrinol. 2019;181(2):57-71. doi: 10.1530/EJE-19-0124.
- Agrawal N., loachimescu A.G. Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review. Pituitary. 2020;23(5):582-94. doi: 10.1007/s11102-020-01063-x.
- Alquraini H., Schneider M.D.P., Mirakhur B., Barcan A. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naive to somatostatin-receptor ligands: analysis of three multicenter clinical trials. Pituitary. 2018;21(3):283-89. doi: 10.1007/s11102-018-0867-5.
- Giustina A., Barkhoudarian G., Beckers A., et al. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord Actions. 2020;21(4):667-678. doi: 10.1007/s11154-020-09588-z.
- Puig-Domingo M., Gil J., Sampedro-Nunez M., et al. Molecular profiling for acromegaly treatment: a validation study. Endocr Relat Cancer. 2020;27:375-89. doi: 10.1530/ERC-18-0565.
- Sahakian N., Castinetti F., Brue N., Cuny N. Current and Emerging Medical Therapies in Pituitary Tumors. J. Clin Med. 2022;11(4):955. Doi: 10.3390/ jcm11040955.
- Gomes-Porras M., Cardenas-Salas J., Alvares-Escola C. Somatostatin Analogs in Clinical Practice: A Review. J. MolSci. 2020;21(5):1682. Doi: 10.3390/ ijms21051682.
- Puig-Domingo M., Marazuela M. Precision medicine in the treatment of acromegaly Minerva Endocrinol. 2019;44(2):169- 75. doi: 10.23736/S0391-1977.18.02937-1
- Puig-Domingo M., Bernabeu I., Pico A., etal. Pasireotide in the Personalized Treatment of Acromegaly. Front Endocrinol. (Lausanne). 2021;12:648411. doi: 10.3389/fendo.2021.648411.
- Ku C.R., Melnikov V., Zhang Z., Lee E.J. Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality? Endocrinol Metab. (Seul). 2020;35(2):206-16. Doi: 10.3803/ EnM.2020.35.2.206.
- Kocak B., Durmaz E.S., Kadioglu P., et al. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. Eur Radiol. 2019;29:2731-9. doi: 10.1007/s00330- 018-5876-2.
- Rass L., Rahvar A-H., Matschke J., etal. Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy? Hormones (Athens). 2022;21(1):79-89. doi: 10.1007/s42000-021-00327-w.
- Villa C., Vasiljevic A., Jaffrain-Rea M.L., et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch. 2019;475:687-92. doi: 10.1007/s00428- 019-02655-0.
- Lloyd L.V., Osamura R.Y., Cloppel G., et al. Tumours of the pituitary gland in WHO classification of tumours of endocrine organs. WHO press, Geneva, 2017. P. 19-24.
- Casar-Borota O., Heck A., Schulz S., et al. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide. Clin Endocrinol Metab. 2013;98(11):E1730-39. Doi: 10.1210/ jc.2013-2145.
- Ezzat S., Caspar-Bell G.M., Chik C.L., etal. Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline. Endocr Pract. 2019;25(4):379- 93. doi: 10.4158/EP-2018-0500.
- Анциферов М.Б., Пронин Е.В., Алексеева Т.М., Пронин В.С. Предикторы эффективности медикаментозной терапии акромегалии (по данным Московского регистра). Фарматека. 2020;27(4):50-56. doi: 10.18565/ pharmateca.2022.0.50-56.
- Coopmans E., Korevaar TJ.M., van Meyel S.W.F., et al. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. J. Clin Endocrinol Metab. 2020;105(9):dgaa387. doi: 10.1210//clinem/ dgaa387.
- Fleseriu M., Biller B.M.K., Freda PU., et al. A Pituitary Society update to acromegaly management guidelines. Pituitary, 2021;24(1):1-13. Doi. org/10.1007/s11102-020-01091-7.
- Kasuki L., Wildemberg L.E., Gadelha M. Management of endocrine disease: Personalized medicine in the treatment of acromegaly. Eur J. Endocrinol. 2518;178(3):R89-155. doi: 10.1530/EJE-17-1006.
- Gadelha M.R., Wildemberg L.E., Kasuki L. The Future of Somatostatin Receptor Ligands in Acromegaly. J. Clin Endocrinol Metab. 2022;107(2):297-308. doi: 10.1210/olinem/dgab726.
- Nista F., Corica G., Castelletti L., et al. Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. Front Endocrinol. (Lausanne). 2021;12:677919. doi: 10.3389/fendo.2021.677919.
- Wildemberg L.E., da Silva Camacho A.H., Miranda R.L., et al. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. J Clin Endocrinol Metab. 2021;16,106(7):2047-56. doi: 10.1210/clinem/dgab125
- Liu W., Xie L., He M., et al. Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues. Int J. Endocrinol. 2017;2017:9606985. doi: 10.1155/2017/9606985.